You are here

  • Home
  • Archive
  • Volume 78, Issue 7
  • Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phas…

Article metrics

Article menu

Download PDFPDF

XML
Rheumatoid arthritis
Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial

 

Online download statistics by month:

Online download statistics by month: April 2019 to August 2023

AbstractFullPdf
Apr 201913413633
May 201916531683649
Jun 201911171087321
Jul 2019540509241
Aug 2019343303138
Sep 2019252200103
Oct 2019311265110
Nov 201930526270
Dec 201923519967
Jan 202015813656
Feb 202012610341
Mar 202012711261
Apr 202013710660
May 2020121106127
Jun 2020917953
Jul 2020877938
Aug 2020878532
Sep 2020968026
Oct 2020898630
Nov 2020665737
Dec 20208068108
Jan 2021716830
Feb 2021605555
Mar 2021817648
Apr 2021473830
May 20211059443
Jun 2021797540
Jul 2021635534
Aug 2021605537
Sep 2021544822
Oct 2021494529
Nov 2021655934
Dec 2021474134
Jan 2022665124
Feb 2022615831
Mar 202210610120
Apr 2022727020
May 2022797330
Jun 2022908726
Jul 2022726924
Aug 2022716747
Sep 2022837423
Oct 2022727424
Nov 2022737018
Dec 2022846922
Jan 2023807733
Feb 2023807216
Mar 2023665922
Apr 2023625622
May 2023454014
Jun 2023676419
Jul 2023403916
Aug 2023383612
Total834377563300